Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Calabrò

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
World Journal of Urology|October 13, 2019
Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohortMariaconsiglia Ferriero, Riccardo Mastroianni, Cosimo De Nunzio, et al.
Journal of Kidney Cancer and VHL|October 20, 2025
Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI StudyGiulia Airò, Annalisa Guida, Alessio Gili, et al.
Oncology|January 17, 2015
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trialCora N Sternberg, Fabio Calabrò, Sergio Bracarda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trialCora N Sternberg, Daniel P Petrylak, Oliver Sartor, et al.
The Oncologist|March 18, 2020
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune DisordersAndrea Antonuzzo, Fabio Calabrò, Pietro Quaglino, et al.
Clinical Genitourinary Cancer|March 4, 2025
Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 TrialsPatrizia Giannatempo, Jean-Pascal Machiels, Naoto Sassa, et al.
Cancers|April 27, 2024
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint InhibitorsSara Mokbel, Giuilia Baciarello, Pernelle Lavaud, et al.
Cancers|October 14, 2023
Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter CohortMariaconsiglia Ferriero, Francesco Prata, Umberto Anceschi, et al.
Clinical & Experimental Metastasis|June 8, 2024
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 projectAlessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, et al.
Frontiers in Oncology|December 5, 2018
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC DatabaseGabriella Del Bene, Fabio Calabrò, Diana Giannarelli, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
World Journal of Urology|October 13, 2019
Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohortMariaconsiglia Ferriero, Riccardo Mastroianni, Cosimo De Nunzio, et al.
Journal of Kidney Cancer and VHL|October 20, 2025
Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI StudyGiulia Airò, Annalisa Guida, Alessio Gili, et al.
Oncology|January 17, 2015
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trialCora N Sternberg, Fabio Calabrò, Sergio Bracarda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trialCora N Sternberg, Daniel P Petrylak, Oliver Sartor, et al.
The Oncologist|March 18, 2020
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune DisordersAndrea Antonuzzo, Fabio Calabrò, Pietro Quaglino, et al.
Clinical Genitourinary Cancer|March 4, 2025
Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 TrialsPatrizia Giannatempo, Jean-Pascal Machiels, Naoto Sassa, et al.
Cancers|April 27, 2024
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint InhibitorsSara Mokbel, Giuilia Baciarello, Pernelle Lavaud, et al.
Cancers|October 14, 2023
Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter CohortMariaconsiglia Ferriero, Francesco Prata, Umberto Anceschi, et al.
Clinical & Experimental Metastasis|June 8, 2024
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 projectAlessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, et al.
Frontiers in Oncology|December 5, 2018
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC DatabaseGabriella Del Bene, Fabio Calabrò, Diana Giannarelli, et al.
Pageof 8